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        NK cell activation is fi   ne tuned by 
integrated signals delivered via acti-
vating and inhibitory receptors. The 
activating receptor NKG2D, which is 
expressed on NK cells, NKT cells, 
         
+   T cells, and some CD8 
+   T cells, 
is critical for NK cell activation (for 
review see reference [  1  ]). Crossing 
NKG2D-defi   cient mice with trans-
genic mouse models of cancer, for 
example, accelerated tumor growth, 
demonstrating the importance of 
NKG2D in tumor immunosurveil-
lance (  2  ). 
  NKG2D binds to a variety of li-
gands that resemble MHC class I pro-
teins (for review see reference [  3  ]). 
Mouse NKG2D ligands include the 
family of retinoic acid inducible genes-
1 (RAE-1            ), the minor histocom-
patibility antigen H60, two H60 
variants (H60b and H60c), and mouse 
UL16-binding protein  –  like transcript 
1 (MULT1) (  4, 5  ). Human ligands in-
clude retinoic acid early transcript-1 
proteins (RAET-1, originally called 
UL16-binding proteins [ULBPs]) and 
the highly polymorphic MHC class I 
chain  –  related proteins A and B (MICA 
and MICB). To date, at least nine li-
gands for mouse NKG2D and seven 
ligands for human NKG2D have been 
reported, and it is likely that this list is 
not yet complete. 
  NKG2D ligands are selectively de-
tected on the cell surface of distressed, 
virus-infected, or malignant cells, but 
rarely on healthy cells, and their ex-
pression must be tightly controlled to 
avoid destruction of healthy cells. On 
page 287 of this issue, Nice et al. 
describe a new way in which MULT1 
expression is controlled in healthy 
cells that involves ubiquitin-dependent 
lysosomal degradation of MULT1 
protein (  6  ). 
  Why so many ligands 
for one receptor? 
  When NKG2D ligands were fi  rst dis-
covered, it was astonishing that there 
were multiple polymorphic ligands 
for one single nonpolymorphic re-
ceptor. Researchers initially suspected 
that more receptors for these ligands 
must exist, but so far none have been 
described. The concept thus emerged 
that the multiple NKG2D ligands 
help ensure that virus-infected and 
malignant cells are effi   ciently recog-
nized by the NKG2D receptor. Evo-
lutionary pressure to avoid escape 
mechanisms devised by certain vi-
ruses and cancers may have driven 
the diversity of NKG2D ligands. 
Moreover, diff  erent NKG2D ligands 
bind with distinct affi     nities to the 
NKG2D receptor, which may fi  ne 
tune the extent of NK cell activation 
via NKG2D (  7  ). 
  The expression of NKG2D li-
gands falls into two general catego-
ries. Transcripts of some ligands, 
such as RAE-1, are rarely expressed 
in healthy tissues but are detectable 
in tumors, virus-infected cells, and 
during embryogenesis. Transcripts 
of other ligands, including the MICs, 
ULBPs, and MULT1, are widely de-
tectable in both healthy and diseased 
tissues. The extent of cell surface 
expression of these ligands, how-
ever, has not been conclusively 
addressed. Mechanisms that ensure 
cell surface expression of NKG2D 
ligands on distressed, but not on 
healthy cells, include cell- and tis-
sue-specific stimuli that control both 
transcriptional and posttranscrip-
tional processes. 
  Transcriptional regulation 
of NKG2D ligands 
  The molecular mechanisms that con-
trol NKG2D ligand expression at the 
transcriptional level are incompletely 
understood, and most promoters of 
NKG2D ligands remain poorly char-
acterized (  Fig. 1 A  ). RAE-1 molecules 
were initially identifi   ed by their in-
duction in response to retinoic acid 
(RA) in a teratoma cell line, and a 
retinoic acid  –  inducible element was 
mapped in the promoter of   Rae-1      , 
suggesting that gene expression is di-
rectly induced by RA (  8  ). Human 
MICA and MICB proteins were also 
up-regulated upon treatment with RA 
in hepatocellular carcinoma cells (  9  ). 
The promoters of the   MICA   and 
  MICB   genes contain heat shock ele-
ments similar to those found in   HSP70   
genes, which inducibly bind to heat 
shock factor-1 (  10  ). Mouse embryonic 
fi  broblasts defi  cient in JunB, a subunit 
of the transcription factor AP-1, also 
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  Intriguingly, transcripts of mouse 
MULT1 have been detected in healthy 
tissues, including the thymus, although 
cell surface expression on thymocytes 
was not detected. In this issue, Nice 
et al. show that mouse MULT1 is ubiq-
uitinated in normal cells, leading to its 
lysosomal degradation and preventing 
its expression at the cell surface (  6  ). In 
response to heat shock or UV irradia-
tion, ubiquitination of MULT1 was 
reduced. Genotoxic shock, on the other 
hand, had no eff  ect on MULT1 ubiqui-
tination. Therefore, heat shock might 
operate by two distinct mechanisms to 
up-regulate diff  erent NKG2D ligands. 
It activates the transcription of ligands 
such as MICA and MICB that contain 
heat shock promoter elements, and it 
inhibits the posttranslational degrada-
tion of other ligands, such as MULT1. 
  UV irradiation might likewise 
control diff   erent NKG2D ligands by 
diff   erent mechanisms. UV irradiation 
induces the activity of AP-1, which has 
been shown to control RAE-1     ex-
pression, most likely by direct transcrip-
tional regulation. And, as shown by 
Nice et al., UV irradiation also inhibits 
the ubiquitination and degradation of 
MULT1 (  6  ). Whether UV irradiation 
and heat shock operate via similar mech-
anisms to induce MULT1 cell surface 
expression is currently unknown. Some 
tumor cells, such as YAC-1 cells, con-
stitutively express MULT1, although it 
is unclear why MULT1 is not degraded 
in these cells. Tumor cells might consti-
tutively activate heat shock responses 
that potentially counteract the degrada-
tion of MULT1, or they might be miss-
ing thus far unidentifi  ed components of 
the ubiquitination and/or degradation 
pathways. Future studies will be required 
to determine whether proteasome in-
hibitors further up-regulate MULT1 
expression on tumor cells that already 
constitutively express the protein. 
  ULPB transcripts were initially 
found in various tissues in healthy indi-
viduals, including heart, lung, liver, and 
testis (  21  ). MICA and MICB transcripts 
were also found in multiple tissues, with 
the exception of the central nervous 
system (  22  ). Notably, MICA protein 
expression was exclusively detected on 
  Posttranscriptional 
and posttranslational 
regulation of NKG2D ligands 
  The recent discovery of posttranscrip-
tional and posttranslational mecha-
nisms of NKG2D ligand regulation 
has added more complexity to the 
picture (  Fig. 1 B  ). IFN-     was reported 
to decrease the expression of human 
MICA and ULBP-2 on melanoma 
cells (  15  ) and of the mouse NKG2D 
ligand H60 on sarcomas (  16  ). An IFN-
      –  inducible microRNA was shown to 
mediate the down-regulation of MICA 
(  17  ). MICA and MICB can also be 
shed from tumor cells by metallopro-
teinases ( 18, 19 ) in a process that requires 
the cell surface endoplasmic reticulum 
5 protein (ERp5) ( 20  ). Soluble MICA/
B and ULBP-2 can be detected in the 
serum of cancer patients, but not in 
healthy individuals, suggesting that 
tumors may exploit down-regulation 
of NKG2D ligands to escape from NK 
cell recognition. 
up-regulate   Rae-1       transcripts (  11  ). 
Although several AP-1 binding sites 
were identifi   ed within the   Rae-1       
promoter, the function of these sites 
was not investigated. Furthermore, 
transcripts of all RAE-1 family mem-
bers, but not of MULT1 or H60, are 
induced in macrophages by Toll-like 
receptor ligands (  12  ). DNA-damaging 
agents, including ionizing radiation, 
5-FU, aphidicolin, cisplatin, and UV-C 
(  13  ), induce the expression of NKG2D 
ligands via ataxia telangiectasia mu-
tated (ATM) or ATM- and Rad3-
  related (ATR) protein kinases. Finally, 
oncogenes such as adenovirus E1A (  14  ) 
up-regulate NKG2D ligand expression. 
To date, however, the exact molecular 
events linking the DNA damage path-
way or the expression of oncogenes to 
up-regulation of NKG2D ligand tran-
scripts and cell surface expression re-
main elusive and may involve both 
transcriptional and posttranscriptional 
events (  Fig. 1  ).   
    Figure 1.         Transcriptional and posttranscriptional regulation of NKG2D ligands.   (A) RA, TLR 
ligands, heat shock, and the transcription factor AP-1 induce the expression of certain NKG2D li-
gands, most likely via direct transcriptional regulation. The molecular mechanisms behind DNA 
damage  –   or oncogene-induced regulation of NKG2D ligands are incompletely understood. (B) Mech-
anisms of posttranscriptional regulation of NKG2D ligands include inhibition by microRNAs (miRNA) 
and metalloproteinase-induced shedding from the cell surface. Nice et al. report in this issue that 
MULT1 is ubiquitinated and degraded by the lysosome in healthy cells. Heat shock or UV irradiation 
decreases ubiquitination and induces MULT1 cell surface expression. It is currently unknown how 
tumor cells achieve cell surface expression of MULT1.     JEM VOL. 206, February 16, 2009  267
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up-regulate NKG2D ligand expression 
on tumor cells in vitro. Whether this 
also occurs in vivo, and whether the 
resulting increase in NKG2D ligand 
expression could activate NK cells in 
cancer patients, remains to be seen. In 
this context, it has been shown that 
chronic exposure to NKG2D ligands 
and soluble MIC that exists in the 
serum of some cancer patients down-
regulates NKG2D expression and leads 
to deactivation of NK cells. This deac-
tivation could be circumvented by 
therapeutic blockade of MIC shedding 
and/or subsequent adoptive transfer of 
NK cells. Small molecular compounds 
that induce NKG2D ligand expression 
on tumor cells combined with a NK 
cell  –  activating regimen could thus 
improve current clinical protocols in 
the treatment of cancer. 
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quently alert the adaptive immune 
system. 
  The selective up-regulation of 
NKG2D ligands on tumor cells is one 
attractive approach. Small molecules that 
have been tested as antitumor agents, 
including the DNA damage-inducing 
cisplatin and 5-FU, up-regulate NKG2D 
ligands (  13  ). The histone deacetylase 
inhibitor sodium valproate, currently 
being evaluated in clinical trials, also 
up-regulates NKG2D ligands (  26  ). 
Moreover, low-dose application of 
the proteasome inhibitor bortezomib 
enhances expression of the human 
NKG2D ligands MICA and MICB on 
hepatocellular carcinoma cells (  27  ). In 
this study, ligand induction occurred at 
both the transcriptional and cell surface 
protein levels, suggesting that multiple 
mechanisms were involved. 
  In their study, Nice et al. report 
that treatment of thymocytes with 
proteasome inhibitors induced MULT1 
expression (  6  ). However, it is unlikely 
that thymocytes are attacked by NK 
cells because they also express high 
levels of self-MHC class I molecules, 
which trigger inhibitory NK cell recep-
tors. Tumors, on the other hand, are 
often characterized by low MHC class I 
expression. The treatment with protea-
some inhibitors that further up-regulate 
NKG2D ligand expression on their cell 
surface might render these tumors highly 
susceptible to NK cell  –  mediated killing. 
  Open questions 
  10 yr after the discovery of NKG2D 
ligands, we are still far from a compre-
hensive understanding of their com-
plex biology. Nice et al. (  6  ) present a 
novel posttranslational control mecha-
nism involving ubiquitination of the 
NKG2D ligand MULT1. The identi-
fi   cation of the ubiquitin ligase and 
additional molecular events involved 
in this pathway will help us to under-
stand why this mechanism operates 
in healthy cells, but not in tumor cells. 
It will also be crucial to provide exper-
imental proof of the role of ubiqui-
tination in the regulation of human 
NKG2D ligands. 
  Several small molecular compounds 
that are currently used in clinical trials 
enterocytes by immunohistochemistry 
staining (  23  ). It is possible that cell sur-
face expression of the transmembrane 
proteins MICA, MICB, and RAET-
1G, which possess lysine residues within 
their cytoplasmic tails, is also controlled 
by ubiquitination. An additional post-
translational mechanism must exist to 
control the cell surface expression of 
ULBP family members that are GPI-
anchored proteins. 
  The concept that NKG2D ligand 
expression can be controlled by ubiqui-
tinylation is not completely new. The 
E3 ubiquitin ligase K5 from Kaposi sar-
coma virus was shown to down-  regulate 
cell surface expression of MICA by 
ubiquitination of lysine residues in the 
protein  ’  s cytoplasmic tail (  24  ). How-
ever, this ubiquitination did not corre-
late with an increased rate of degradation, 
but rather in a redistribution of MICA 
from the plasma membrane to an intra-
cellular compartment. Therefore, even 
subsequent to ubiquitination, distinct 
mechanisms exist to control expression 
of diff  erent NKG2D ligands. 
  Multiple checkpoints operating 
at diff   erent levels of NKG2D ligand 
protein synthesis not only facilitate the 
expression of NKG2D ligands during 
diff  erent types of stress but might also 
fi   ne tune the kinetics of cell surface 
expression. It is feasible that posttransla-
tional regulation allows more rapid 
expression of NKG2D ligands on the 
surface of virus-infected or tumor cells 
than could be achieved via transcrip-
tional regulation, thus ensuring rapid 
elimination of unhealthy cells. 
  NKG2D ligands in cancer therapy 
  Harnessing the natural ability of NK 
cells to attack tumors is a relatively new 
approach to cancer therapy (for review 
see reference [  25  ]). Although NK cells 
are eff  ective killers of most tumor cell 
lines in vitro, it is obvious that they 
do not eff   ectively eliminate tumors 
in cancer patients. Strategies aimed at 
increasing both NK cell activation and 
tumor cell visibility to NK cells are cur-
rently being developed. These strategies 
will facilitate direct NK cell  –  mediated 
killing of tumor cells, and there is evi-
dence that dying tumor cells subse-268 REGULATION OF NKG2D LIGANDS| Cerwenka
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